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Invariant natural killer T (iNKT) cells, which are activated by T cell receptor
(TCR)-dependent recognition of lipid-based antigens presented by the CD1d molecule,
have been shown to participate in the pathogenesis of many diseases, including asthma
and liver injury. Previous studies have shown the inhibition of iNKT cell activation
using lipid antagonists can attenuate iNKT cell-induced disease pathogenesis. Hence,
the development of iNKT cell-targeted glycolipids can facilitate the discovery of new
therapeutics. In this study, we synthesized and evaluated α-lactosylceramide (α-LacCer),
an α-galactosylceramide (α-GalCer) analog with lactose substitution for the galactose
head and a shortened acyl chain in the ceramide tail, toward iNKT cell activation.
We demonstrated that α-LacCer was a weak inducer for both mouse and human
iNKT cell activation and cytokine production, and the iNKT induction by α-LacCer
was CD1d-dependent. However, when co-administered with α-GalCer, α-LacCer
inhibited α-GalCer-induced IL-4 and IFN-γ production from iNKT cells. Consequently,
α-LacCer also ameliorated both α-GalCer and GSL-1-induced airway hyperreactivity
and α-GalCer-induced neutrophilia when co-administered in vivo. Furthermore, we were
able to inhibit the increases of ConA-induced AST, ALT and IFN-γ serum levels through
α-LacCer pre-treatment, suggesting α-LacCer could protect against ConA-induced liver
injury. Mechanistically, we discerned that α-LacCer suppressed α-GalCer-stimulated
cytokine production through competing for CD1d binding. Since iNKT cells play a critical
role in the development of AHR and liver injury, the inhibition of iNKT cell activation by
α-LacCer present a possible new approach in treating iNKT cell-mediated diseases.
Keywords: NKT cell, glycolipid, CD1d, asthma, liver injury, ConA
INTRODUCTION
Invariant natural killer T (iNKT) cells are a rare subset of T cells that possess properties of both
conventional T and natural killer (NK) cells (Wu and Van Kaer, 2011; Cameron et al., 2015).
Unlike conventional T cells, iNKT cells express a highly restricted T cell receptor (TCR)-α chain
(Vα14/Jα18 in mice and Vα24/Jα18 in humans) and a moderately diverse TCR-β chain (Vβ2, Vβ7,
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and Vβ8 in mice and Vβ11 in humans; Carreno et al.,
2016). iNKT cells are activated through invariant TCR by the
recognition of lipid-based antigens presented by the MHC class
I-like CD1d molecule found on antigen presenting cells (Laurent
et al., 2014; Cameron et al., 2015). Activated iNKT cells produce
large quantities of cytokines including the Th2 cytokine IL-4 and
the Th1 cytokine IFN-γ, which can enhance the function of other
immune cells such as NK, B and T cells (Carnaud et al., 1999;
Kitamura et al., 2000; Brigl et al., 2003). Therefore, iNKT cells
play a key role in bridging the innate and adaptive immunity.
Due to their restricted TCR rearrangements, all iNKT cells
share the ability to recognize glycolipids with their sugar head
attached in an α-anomeric configuration to the polar head group
of a lipid (Kjer-Nielsen et al., 2006). α-galactosylceramide (α-
GalCer), also known as KRN7000, is the prototypical glycolipid
of this type and has the capability to activate all iNKT cells
with a mixed Th1 and Th2 response when presented by
CD1d molecule (Kawano et al., 1997; Zhang et al., 2008).
α-Glucuronosylceramide (GSL-1), a glycolipid extracted from
Sphingomonas bacteria, represents another CD1d ligand with α-
linked glucuronic acid and a mixture of at least three different
sphingosine bases (Perola et al., 2002; Kinjo et al., 2005). Similar
to α-GalCer, GSL-1 is also a potent stimulator of iNKT cells,
primarily by engaging the TCR expressed by these cells (Perola
et al., 2002; Kinjo et al., 2005; Long et al., 2007). Consequently,
both α-GalCer and GSL-1 are commonly used to study the
function of iNKT cells or iNKT cell-related diseases.
iNKT cells have been implicated in a number of immune-
related diseases due to their multi-functional responses.
Activated iNKT cells can enhance tumor immunity (Kawano
et al., 1999; Aspeslagh et al., 2013) as well as suppress
autoimmune disease (Singh et al., 2001). However, they are
also associated with the disruption of mucosal homeostasis in
the intestines and airways (Nau et al., 2014) and contribute
to allergic airway inflammation in various allergen models,
including ovalbumin (OVA) and house dust mite (HDM)
extract, through Th2-biased cytokine responses (Akbari
et al., 2003; Lisbonne et al., 2003; Wingender et al., 2011).
Furthermore, both α-GalCer and GSL-1 have been shown
to induce airway hyperreactivity (AHR) through iNKT cell
activation as glycolipid-induced AHR was abolished in iNKT
cell-deficient CD1d−/− (human CD1d analog) and Jα18−/−
mice (Meyer et al., 2006). Additionally, iNKT cells also contribute
to concavalin A (ConA)-induced hepatitis by inducing liver
injury (Kaneko et al., 2000; Takeda et al., 2000). Given their
pathogenic roles, the development of lipid antagonist that
limit the activation of pathogenic iNKT cells may be of
therapeutic relevance.
In this paper, we examined the effects of α-lactosylceramide
(α-LacCer), an α-GalCer analog with a lactose head instead of
galactose head and a shortened acyl chain in the ceramide tail,
on iNKT cells. We found that α-LacCer weakly induced mouse
and human iNKT cell activation in a CD1d-dependent manner.
However, when co-treated with α-GalCer, α-LacCer suppressed
the iNKT cell-activating properties of α-GalCer in terms of
IL-4 and IFN-γ production. The therapeutic application of α-
LacCer was evaluated in vivo, in which this glycolipid effectively
attenuated α-GalCer- and GSL-1-induced AHR and Con-A-
mediated liver injury. Lastly, our results in the plate-bound CD1d
binding assay suggested the inhibitory function of α-LacCer was
mediated by competitive CD1d binding.
MATERIALS AND METHODS
Mice
Eight- to ten-week-old C57BL/6 and BALB/c female mice were
purchased from National Laboratory Animal Center (Taipei,
Taiwan). CD1d−/− (human CD1d analog) mice (Stock No:
002962) were purchased from The Jackson Laboratory (Maine,
USA). All animals were housed under specific pathogen-free
conditions. This study (13-03-525) was carried out in accordance
with the recommendations and guidelines of Academia Sinica
Institutional Animal Care and Use Committee (IACUC), and all
protocols were approved by the IACUC.
Reagents
α-GalCer (KRN7000) was purchased from Funakoshi (Tokyo,
Japan). RPMI 1640, DMEM, newborn calf serum (NBCS), and
red blood cell (RBC) lysis buffer were purchased from GibcoTM
(Waltham, MA, USA). Fetal bovine serum (FBS) was purchased
from Biological Industries (Beit-Haemek, Israel). Recombinant
mouse IL-2 and GM-CSF were purchased from BioLegend (San
Diego, CA, USA). Recombinant mouse IL-15, human IL-4, and
GM-CSF were purchased from PeproTech (Rocky Hill, NJ, USA).
Recombinant human IL-2 was purchased from eBioscience (San
Diego, CA, USA).
In vitro Stimulation of Mouse Vα14+T
Hybridomas, Splenocytes, and iNKT Cells
Vα14+T hybridomas (NK1.2), A20 and A20-CD1d cells, which
were maintained in cRPMImedium, were kindly provided by Dr.
Mitchell Kronenberg (La Jolla Institute, CA). For mouse Vα14+T
hybridoma stimulation, NK1.2 cells (105) were co-cultured with
A20 or A20-CD1d cells (5× 104) and stimulated with glycolipid.
Splenic iNKT cells were expanded with α-GalCer, and CD1d
tetramer+ TCRβ+ cells were sorted by FACSAria (BD Bioscience,
San Jose, CA, USA) with a purity of>95%, and sorted iNKT cells
were cultured with IL-2 and IL-15 and rested for 24 h before use.
For mouse iNKT cell stimulation, sorted mouse iNKT cells (105)
were co-cultured with irradiated GM-CSF-treated bone marrow-
derived dendritic cells (3 × 104) and before stimulation with
glycolipids. Mouse splenocytes (106) were isolated from fresh
mouse spleen via mechanical dissociation before stimulation
with glycolipids. Neutralization of CD1d was performed with 0.5
µg/well of anti-CD1d antibody (1B1, eBioscience).
In vitro Culture of Human PBMCs and iNKT
Cells
Human peripheral blood mononuclear cells (PBMCs) from
healthy volunteers were collected from whole blood through
gradient-centrifugation with Histopaque-1077 (Sigma-Aldrich).
Human iNKT cells were isolated from PBMCs as described
previously (Kim et al., 2011). This study (AS-IRB-BM-15054 v.1)
was carried out in accordance with the recommendations and
Frontiers in Chemistry | www.frontiersin.org 2 November 2019 | Volume 7 | Article 811
Lai et al. α-Lactosylceramide Suppresses iNKT-Mediated Inflammation
guidelines of Academia Sinica Institutional Review Board on
Biomedical Science Research (IRB-BM) with written informed
consent from all subjects. All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The
protocol was approved by the IRB-BM. 0.5 µg/well of anti-CD1b
antibody (SN13, BioLegend) and anti-CD1d antibody (51.1,
BioLegend) were used for blocking CD1b andCD1d, respectively.
Measurement of Airway Hyperreactivity in
Mice
BALB/c mice were intranasally (i.n.) administered with 1 µg of
α-GalCer or 10 µg of GSL-1 in the presence or absence of 1 µg
α-LacCer for 24 h. Mice were anesthetized with 100 mg/kg in
body weight of pentobarbital (Sigma-Aldrich), tracheotomized
andmechanically ventilated via the FinePointe RC system (Buxco
Research Systems, Wilmington, NC, USA). AHR was assessed
by measuring the lung resistance and dynamic compliance in
response to increasing doses of aerosolized methacholine (1.25–
40 mg/mL, Sigma-Aldrich).
Collection and Analysis of BALF From Mice
Upon exposure of trachea, the airway was lavaged twice with
1ml of PBS supplemented with 2% FCS. BALF was pooled, and
cells were pelleted by centrifugation and fixed onto slides. The
slides were stained with Diff-Quik solution (Polysciences Inc.),
and differential cell count was performed.
Murine Lung Cell Isolation
The whole lungs were flushed by PBS injection (supplemented
with 2% FCS) through the right ventricle and minced prior
to incubation in 3ml DMEM medium with 0.1% (v/v) DNase
I (Worthington Biochemicals) and 1.6 mg/mL collagenase IV
(Worthington Biochemicals) for 40min at 37◦C. Tissues were
filtered through a 100µmmesh to obtain single cell suspensions.
Red blood cells were removed by incubating in ACK lysing
buffer (GIBCO) for 5min at 25◦C. Single cell suspensions were
suspended in the appropriate buffer for further processing.
Flow Cytometry
Single cell suspensions were stained with fixable viability dye
eFluor R© 780 (eBioscience) for 30min at 4◦C, and Fc receptors
were blocked with anti-CD16/32 (BioLegend) blocking antibody
prior to surface staining with antibodies. Antibodies for surface
staining used are listed, mouse: CD45 (30-F11, BioLegend),
TCR β (H57-597, BioLegend), CD69 (H1.2F3, eBioscience),
CD1d tetramer (NIH); human: CD45 (HI30, eBioscience),
TCRα/β (IP26, BioLegend), CD69 (FN50, BioLegend), Vα24
(6B11, BD Bioscience). For intracellular staining, single cell
suspensions were stimulated with 50 ng/mL phorbol 12-myristate
13-acetate (PMA) (Sigma-Aldrich), 1µg/mL ionomycin (Sigma-
Aldrich) and 1µg/mL Golgi stop A (BD Biosciences) for
4 h. After surface staining, cells were fixed and permeabilized
with Cytofix/Cytoperm solution (BD biosciences) and further
stained intracellularly with human IFNγ (B27, BioLegend)
and human IL-4 (MP4-25D2, BioLegend). For Ki67 staining,
cells were fixed and permeabilized with Cytofix/Cytoperm
solution (eBioscience), and further stained with Ki67 (SolA15,
eBioscience). Data were acquired using LSR II (BD Biosciences)
and analyzed using the FlowJo software (BD Biosciences).
Murine ConA-Induced Liver Injury Model
BALB/c or CD1−/− mice were injected intravenously (i.v.) with
25mg/kg ConA (Sigma-Aldrich) for 24 h. In α-LacCer protection
experiments, BALB/c mice were pre-treated with 5µg/ml α-
LacCer (i.p.) for 24 h prior to ConA treatment. Serum was
collected at 0, 6, and 24 h for aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) detection, and livers were
harvested at 24 h post-injection for H&E staining.
Plate-Bound CD1d Binding Assay
96-well strepavidin plates (Thermo scientific) were incubated
with 0.5 µg of mouse CD1 or human CD1d monomer protein
per well in PBS for 24 h in dark at room temperature. Plate was
washed with PBS twice, and indicated glycolipids were loaded
and incubated overnight under 37◦C. After 24 h, the plate was
washed twice, and 105 iNKT cells were added and cultured for
48 h. The supernatant was harvested, and the levels of IFN-γ and
IL-4 were detected by ELISA.
ELISA
Cytokines (mouse IL-2, IL-4, and IFNγ; human IFNγ and
IL-4) in culture supernatant, lung lysate, serum, or BALF of
mice were analyzed with ELISA kits from Biolegend, with the
exception of mouse IL-13 (eBioscience). For the determination of
cytokine concentrations in vivo, lungs were flushed and minced
thoroughly prior to sonication with Bioruptor R© Plus sonicator
(Diagenode) in RIPA buffer. Lung protein lysate was obtained
via centrifugation. To determine cytokine concentrations in the
serum, blood samples collected from mice were incubated at
room temperature to allow coagulation and the collection of sera.
Statistics
Data were analyzed with the GraphPad Prism software
(GraphPad Prism software, San Diego, CA, USA). Statistical
analysis was determined using the Student’s two-tailed t-test and
the two-way analysis of variance (ANOVA).
RESULTS
α-LacCer Activates NK1.2 Hybridoma and
Mouse iNKT Cells in a CD1d-Dependent
Manner
The synthetic protocol of α-LacCer, a new α-GalCer analog with
lactose substitution at the galactose head (Hsieh et al., 2014),
is shown in Supplementary Figure 1, where a trimethylsilyl
protected ceramide was reacted with an activated lactosyl iodide
to give the alpha-lactoside in 61% purified yield. Deprotection of
the acetate protecting groups quantitatively afforded the desired
material for this study. The structures of α-GalCer and α-LacCer
are shown in Figure 1A, respectively.
We first assessed their immune-stimulating activities in both
Vα14+T hybridoma cells (NK1.2) and primary mouse iNKT
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FIGURE 1 | α-LacCer activates NK1.2 hybridoma and mouse iNKT cells in a CD1d-dependent manner. (A) The structures of α-galactosyl ceramide (α-GalCer) and its
analogs, α-lactosyl ceramide (α-LacCer). (B) Vα14+ T hybridoma cells (NK1.2) were co-cultured with A20-CD1d cells in the presence of α-GalCer (100, 1,000 ng/ml)
or α-LacCer (10, 100, 1,000 ng/ml) for 48 h. The level of IL-2 in the supernatant was measured (n = 3–4). (C,D) Sorted mouse iNKT cells in co-culture with irradiated
BMDCs were stimulated with α-GalCer (100 ng/ml) or α-LacCer (10, 100, 1,000 ng/ml) for 48 h, and the levels of IFN-γ (C) and IL-4 (D) in the supernatant were
measured (n = 3). (E,F) Sorted mouse iNKT cells in co-culture with irradiated CD1d−/− or WT BMDCs were stimulated with α-GalCer (100 ng/ml) or α-LacCer
(100 ng/ml) for 48 h. The levels of IFN-γ (E) and IL-4 (F) in the supernatant were measured (n = 3). Data are representative of three independent experiments and
presented as means ± s.e.m. [*P < 0.05, **P < 0.01, and ***P < 0.001; Student’s t-test (B–F)].
cells. In comparison to α-GalCer, α-LacCer induced a lower level
of IL-2 production by NK1.2 cells (Figure 1B). Similarly, the
levels of IFN-γ (Figure 1C) and IL-4 (Figure 1D) produced by
α-LacCer-treated iNKT cells co-cultured with DCs were lower
than cells treated with α-GalCer. Moreover, mouse iNKT cells
failed to produce IFN-γ (Figure 1E) and IL-4 (Figure 1F) in
response to both glycolipids when co-cultured with CD1d−/−
DCs, suggesting both α-GalCer and α-LacCer induce mouse
iNKT cell activation in a CD1d-dependent manner.
α-LacCer Suppresses α-GalCer-Induced
Cytokine Production in vitro and in vivo
Since α-LacCer has been shown as a CD1d ligand weakly
inducing iNKT cell activation, we theorized α-LacCer might
be a good candidate to suppress iNKT cell activation by
competing for CD1d-binding. To prove this hypothesis, we co-
treated splenocytes with α-GalCer and α-LacCer. We observed
that α-LacCer co-treatment reduced α-GalCer-induced IFN-
γ (Figure 2A) and IL-4 (Figure 2B) production by mouse
splenocytes. Additionally, α-LacCer inhibited α-GalCer-induced
IL-2 production by NK1.2 hybridomas (Figure 2C), as well as
IFN-γ (Figure 2D) and IL-4 (Figure 2E) production by mouse
iNKT cells co-cultured with DCs. To further determine the
inhibitory characteristic of α-LacCer, we performed a functional
assay using NK1.2 hybridomas and measured the IC50 as
2.917µg/ml against α-GalCer (Figure 2F).
To determine the inhibitory effect of α-LacCer in vivo, BALB/c
mice were injected intraperitoneally with 1 µg α-GalCer in
the presence or absence of 1 µg α-LacCer. We found that
α-LacCer co-treatment reduced α-GalCer-induced lung iNKT
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FIGURE 2 | α-LacCer suppresses α-GalCer-induced cytokine production in
vitro. (A,B) Splenocytes from BALB/c mice were stimulated with 100 ng/ml
α-GalCer in the presence or absence of α-LacCer (5 or 20µg/ml) for 48 h. The
levels of IFN-γ (A) and IL-4 (B) in the supernatant were measured (n = 3).
(C,D) Sorted mouse iNKT cells were co-cultured with irradiated BMDCs and
stimulated with α-GalCer (100 ng/ml) in the presence or absence of α-LacCer
(5 or 20µg/ml) for 48 h. The levels of IFN-γ (C) and IL-4 (D) in the supernatant
were measured (n = 3). (E) NK1.2 cells in co-culture with A20-CD1d cells
were stimulated with 100 ng/ml α-GalCer in the presence or absence of
α-LacCer (100, 1,000, or 10,000 ng/ml) for 48 h. The level of IL-2 in
supernatants was measured (n = 3). (F) NK1.2 cells in co-culture with
A20-CD1d cells were stimulated with 100 ng/ml α-GalCer in the presence of
incremental levels of α-LacCer (0.1–100µg/ml) for 48 h. The level of IL-2 in
supernatants was measured (n = 4), and GraphPad Prism was utilized for
calculating the IC50. Data are representative of three independent experiments
and presented as means ± s.e.m. [n.s., not significant; **P < 0.01 and ***P <
0.001; Student’s t-test (A–F)].
cell activation (Figure 3A) and proliferation (Figure 3B), as
determined by the expressions of CD69 and Ki67, respectively.
Furthermore, mice receiving α-GalCer and α-LacCer showed
lower levels of lung IFN-γ and IL-4 comparing to α-GalCer-
treated mice (Figure 3C). Taken together, these data indicate
that α-LacCer suppress α-GalCer-induced iNKT activation,
proliferation and cytokine production in vitro and in vivo.
α-LacCer Inhibits α-GalCer-Induced Lung
iNKT Cell Activation and Airway
Hyperreactivity (AHR)
Previous studies have shown that activation of lung iNKT cells
by α-GalCer mediated the development of AHR and airway
inflammation (Meyer et al., 2006; Wingender et al., 2011).
Thus, we wondered whether α-LacCer could suppress α-GalCer-
induced AHR.We treated mice intranasally with α-GalCer in the
presence or absence of α-LacCer for 24 h. We found α-LacCer
co-treatment attenuated α-GalCer-induced AHR (Figure 4A)
and neutrophil infiltration in the bronchoalveolar lavage
fluid (BALF) (Figure 4B). Accordingly, α-GalCer-induced IL-
4 and IL-13 production were significantly inhibited by α-
LacCer (Figure 4C). Similar suppression was observed in the
GSL-1-induced AHR model (Figure 4D), further highlighting
the therapeutic potential of α-LacCer for the treatment
of asthma.
α-LacCer Protects Against ConA-Induced
Liver Injury
iNKT cells have been shown to participate in ConA-induced
liver damage (Mattner, 2013). Hence, we examined whether
α-LacCer could protect against iNKT cell-mediated liver
damage. In accordance to a previous study (Takeda et al.,
2000), ConA induced liver damage in WT, but not iNKT cell-
deficient CD1d−/− mice (Figures 5A,B). Likewise, serum
levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were markedly lower in ConA-
treated CD1d−/− mice compared to their WT counterpart
(Figure 5C), implying that ConA-induced hepatitis was
iNKT cell-dependent.
We next examined whether the pre-treatment with α-LacCer
could protect against ConA-induced liver damage. α-LacCer
was injected intraperitoneally 24 h before ConA injection, and
the extent of liver damage was measured. We found that α-
LacCer pre-treatment significantly reduced the percentage of
liver damage area (Figures 5D,E). Similarly, ConA-induced AST,
ALT (Figure 5F), and IFN-γ (Figure 5G) production in sera were
suppressed by α-LacCer. These data demonstrated the protective
effect of α-LacCer against ConA-induced liver injury.
α-LacCer Suppresses α-GalCer-Induced
Activation and Cytokine Production by
Human iNKT Cells
To examine the possible effects of α-LacCer in human,
human iNKT cells were isolated and co-cultured with
irradiated DCs with α-GalCer or α-LacCer in the presence
or absence of anti-human CD1b or anti-human CD1d
antibody. Human iNKT cells showed little to no induction
of IFN-γ and IL-4 when treated with α-LacCer comparing
to α-GalCer (Figure 6A). Additionally, the induction was
CD1d-dependent as blocking CD1d, but not CD1b, impaired
cytokine production induced by α-GalCer. α-LacCer also
failed to induce iNKT cell proliferation (Ki67+ cells) and
activation (CD69+ cells) in terms of percentage (Figure 6B) and
frequency (Figure 6C). Furthermore, α-LacCer co-treatment
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significantly suppressed α-GalCer-induced IFN-γ secretion
from human PBMC (Figure 6D) and human iNKT cells
(Figure 6E). Overall, these data indicated that α-LacCer
effectively inhibited both human and mouse iNKT cell activation
and cytokine production.
α-LacCer Suppresses α-GalCer-Stimulated
Cytokine Production by iNKT Cells by
Competing for CD1d Binding
Since α-LacCer could be docked into both mouse CD1-iNKT
TCR and human CD1d-iNKT TCR complexes (Data not shown),
we hypothesized that the suppressive effect exhibited by α-LacCer
toward α-GalCer might be due to the competitive binding to
CD1d. We examined this hypothesis by performing the cell-
free plate-bound CD1d assay. We pre-loaded mouse CD1d and
human CD1d-coated plates with α-GalCer or α-LacCer, followed
by a second loading with α-LacCer or α-GalCer, respectively.
Pre-loading with α-LacCer reduced α-GalCer-induced IFN-γ
(Figure 7A) and IL-4 (Figure 7B) production in mouse iNKT
cells. Similar results were obtained with human iNKT cells
(Figures 7C,D). In short, our results suggested that α-LacCer
suppressed α-GalCer-stimulated cytokine production by mouse
and human iNKT cells by competing for CD1d binding.
DISUCSSION
In this study, we demonstrated that α-LacCer is a weak
activator of mouse and human iNKT cells comparing to
α-GalCer. Yet, when co-administered with α-GalCer in
vitro, α-LacCer suppressed α-GalCer-induced mouse and
human iNKT cell activation and cytokine production.
Through a NK1.2 hybridoma-based functional assay, we
measured the IC50 of α-LacCer as 2.917µg/ml against
α-GalCer. When co-administered with α-GalCer or GSL-
1 in vivo, α-LacCer suppressed AHR development by
both glycolipids, as well as α-GalCer-induced neutrophilic
inflammation by inhibiting lung iNKT cell activation and
cytokine production. Furthermore, α-LacCer protected
against ConA-induced liver injury in a CD1d-dependent
manner. Lastly, pre-loaded α-LacCer inhibited α-GalCer-
stimulated IL-4 and IFN-γ production by iNKT cells in the
plate-bound CD1d binding assay, suggesting the inhibitory
effect of α-LacCer is due to its competition for CD1d
binding. Results from this study highlighted the potential
therapeutic utility of α-LacCer for the treatment of iNKT
cell-associated diseases.
iNKT cells are associated with various allergic and non-
allergic diseases. For instance, iNKT cells contribute to the
induction of pathology in mucosal tissues of the airways
and the gastrointestinal tract and drive allergic inflammatory
reactions through the production of Th2 cytokines, as well
as the recruitment and degranulation of mast cells and
eosinophils (Nau et al., 2014). iNKT cells also contribute
to lupus development by augmenting Th1-biased immune
responses and autoantibody secretion (Zeng et al., 2003).
Additionally, collagen-induced arthritis (CIA) is associated with
FIGURE 3 | α-GalCer-induced iNKT cell activation and proliferation are
suppressed by α-LacCer in vivo. BALB/c mice were injected intraperitoneally
with 1 µg of α-GalCer and α-LacCer, and the lungs were harvested 3 days
post-injection. (A) Flow cytometry analysis of CD69 and Ki67 expressions in
iNKT cells (CD45+TCRβ+CD1d tetramer+ cells). (B) Absolute numbers of
total, CD69+, and Ki67+ iNKT cells calculated from the flow cytometry data (n
= 3). (C) IFN-γ and IL-4 levels in the lung lysates were measured by ELISA (n
= 3). Data are representative of three independent experiments and presented
as means ± s.e.m. [**P < 0.01 and ***P < 0.001, Student’s t-test (B,C)].
iNKT cells because CIA can be ameliorated by blocking the
interaction between CD1d and iNKT cells using anti-CD1d
neutralizing antibody (Chiba et al., 2005). Furthermore, α-
GalCer treatment in mice often leads to detrimental side
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FIGURE 4 | α-LacCer suppresses α-GalCer and GSL-1-induced airway hyperreactivity. BALB/c mice were treated intranasally with 1 µg α-GalCer (A–C) or 10 µg
GSL-1 (D) in the presence or absence of 1 µg α-LacCer for 24 h. (A,D) Changes in lung resistance (RL ) in response to increasing doses of methacholine [n =
6–8/group in (A); n = 3–5/group in (D)]. (B) The numbers of macrophage (Mac), neutrophil (Neu), eosinophil (Eos), and lymphocyte (Lym) in the BALF (n = 7–8). (C)
The levels of IL-4 and IL-13 in the lungs assessed using ELISA (n = 4). Data are representative of three independent experiments and presented as means ± s.e.m.
[*P < 0.05, **P < 0.01, and ***P < 0.001; Two-way ANOVA (A,D) and Student’s t-test (B,C)].
effects, resulting in disease exacerbation rather than protection
(Wu and Van Kaer, 2009). Hence, the pathogenic roles of
activated iNKT cells in various diseases justify the need to
develop new and improved therapeutic approaches targeting
these cells.
Several lipids have been shown to suppress iNKT cell
activation, but none have been developed pharmacologically.
For instance, An et al. revealed that GSL-Bf717, a bacterial
glycol sphingolipids extracted from Bacteroides fragilis, did not
activate iNKT but could inhibit iNKT hybridoma activation
when treated together with α-GalCer (An et al., 2014). In another
study, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N[methoxy(polyethyleneglycol)-350 (DPPE-PEG350) was
developed and reported to be effective in inhibiting iNKT cell
activation and attenuating the development of allergen-induced
AHR (Lombardi et al., 2010) and atherosclerosis (Li et al.,
2016). Furthermore, a non-lipid based antagonist, Griffonia
simplicifolia-derived isolectin B4 (IB4), has been shown to
inhibit the sphingolipid isoglobotrihexosylceramide (iGb3)-
induced iNKT cell stimulation by binding to the terminal Gal
α1,3 Gal of iGb3, thus preventing its recognition by mouse
Vα14 and human Vα24 iNKT cells (Keusch et al., 2000; Zhou
et al., 2004). Hence, our findings add to the growing list of
iNKT cell antagonists that can be exploited for therapeutic
purposes. Mechanistically, the inhibitory function of α-
LacCer on α-GalCer activity seems to involve the competitive
binding of CD1d. However, this does not mean α-LacCer
prevents the activation of iNKT through the inhibition of
CD1d function. Rather, α-LacCer could still induce iNKT
activation through CD1d while it is occupying the binding
site, but at a much weaker level comparing to α-GalCer. This
speculation is supported by the in vitro data showing that
α-LacCer could activate iNKT in a CD1d-dependent manner,
but with a much lower intensity in comparison to α-GalCer.
However, the exact mechanism may require further investigation
to reveal.
A similar glycolipid with lactose head, also called α-LacCer,
was previously synthesized and found to activate both human
and mouse iNKT cells as effectively as α-GalCer in terms of
inducing IL-4, but not IFN-γ production (Zhang et al., 2008).
This Th2-biased glycolipid exhibited both antitumor and anti-
autoimmune disease effects, with greater potency than α-GalCer
in ameliorating the latter disease. Contrary to this, the α-
LacCer synthesized for our study is a weak iNKT cell activator
when compared with the prototypical α-GalCer, as evidenced
by the lower IFN-γ and IL-4 production, as well as the lack
of iNKT cell expansion and activation when administered in
vivo. The difference in potency is likely due to the different
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FIGURE 5 | α-LacCer protects against ConA-induced liver injury. (A–C) ConA was injected intravenously (25 mg/kg) into BALB/c (n = 3) or CD1d−/− mice (n = 3).
Sera were collected at 0, 6, and 24 h post-injection, and mice were sacrificed at 24 h post-injection. (A) H&E stained liver sections (Scale bar = 500µm). (B)
Percentage of liver damage area. (C) Serum levels of ALT and AST. (D–G) BALB/c mice were first pre-treated intraperitoneally with α-LacCer (5µg/ml) for 24 h and
followed by ConA (25 mg/kg; i.v.) administration. Sera and livers were harvested 24 h post-ConA treatment. (D) H&E stained liver sections (Scale bar = 200µm). (E)
Percentage of liver damage area (n = 3). (F) Serum levels of AST and ALT (n = 4). (G) The serum IFN-γ level measured by ELISA (n = 4). Data are representative of
three independent experiments and are presented as means ± s.e.m. [*P < 0.05, **P < 0.01, and ***P < 0.001; Student’s t-test (B,C,E–G)].
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FIGURE 6 | α-LacCer suppresses α-GalCer-induced cytokine production by human iNKT cells in vitro. (A) Sorted human iNKT cells were stimulated with α-GalCer
and α-LacCer (1µg/ml) in the absence or presence of anti-CD1b or anti-CD1d antibody for 72 h. The levels of IFN-γ and IL-4 in the supernatant were analyzed (n =
3–6). (B,C) Human PBMCs were cultured with 1µg/ml α-GalCer and α-LacCer for 7 days. (B) FACS analysis of CD69, IFN-γ, and IL-4 expressions in human iNKT
cells (CD45+tetra-CD1d+TCRβ+). (C) Absolute numbers of total and CD69+ iNKT cells. (D) Human PBMCs were stimulated with α-GalCer (100 ng/ml) in the
presence or absence of α-LacCer (1µg/ml) for 3 days. The level of IFN-γ was analyzed (n = 3). (E) Human iNKT cells were cultured with irradiated DCs pre-treated
with 100 ng/ml α-GalCer in the absence or presence of 1µg/ml α-LacCer for 3 days. The levels of IFN-γ and IL-4 were analyzed (n = 3–5). Data are representative of
three independent experiments and presented as means ± s.e.m. [n.s., not significant; *P < 0.05, **P < 0.01, and ***P < 0.001; Student’s t-test (A,C–E)].
acyl chain length. The reported α-LacCer retains the 26-
carbon long acyl chain found in the prototypical α-GalCer,
whereas the α-LacCer synthesized in our study is 8 carbons
shorter (C18). Truncation of the acyl chain has previously
been shown to reduce the binding stability of glycolipids to
CD1d without affecting TCR affinity (McCarthy et al., 2007).
While this may explain the weaker activating property of
our α-LacCer, it does not justify the observation that α-
LacCer can effectively suppress α-GalCer-induced iNKT cell
activation and the downstream effects through competitive
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FIGURE 7 | α-LacCer suppresses α-GalCer-stimulated cytokine production by competing for CD1d binding. (A,B) Sorted mouse iNKT cells were cultured in the
CD1-coated plate pre-loaded with 100 ng/ml α-GalCer or 1µg/ml α-LacCer with or without the second loading of α-GalCer or α-LacCer for 48 h. The levels of IFN-γ
(A) and IL-4 (B) in the culture supernatant were assessed (n = 3). (C,D) Sorted human iNKT cells were cultured in the CD1d-coated plate pre-loaded with α-LacCer (1
or 10µg/ml) with the second loading of α-GalCer (100 ng/ml) for 48 h. The levels of IFN-γ (C) and IL-4 (D) in the supernatant were assessed (n = 3–6). Data are
representative of three independent experiments and are presented as means ± s.e.m. [*P < 0.05, **P < 0.01, and ***P < 0.001; Student’s t-test (A–D)].
CD1d binding. Hence, the difference in the activation potency
between the reported α-LacCer and ours may be caused by other
factors, and additional studies will be required to unravel the
mechanisms involved.
We observed that α-LacCer effectively suppressed ConA-
induced liver injury. Although it has been suggested that ConA-
induced liver injury is CD1d-independent (Zeissig et al., 2017),
a recent study reported that CD1d-mediated activation of iNKT
cells is required for further activation of these cells in response to
ConA (Wei et al., 2016). In their study, the authors demonstrated
the importance of gut bacteria-derived glycolipids in driving
hepatic iNKT cell activation. When comparing to specific
pathogen-free mice, germ-free mice had lower levels of gut
bacteria-derived glycolipids and were resistant to ConA-induced
liver injury. Based on this finding, we postulate that α-LacCer
may reduce ConA-induced liver damage by preventing the initial
iNKT cell activation.
In summary, the data indicate that even though α-LacCer
failed to potently activate iNKT cells, it did effectively
suppress the iNKT cell-activating properties of α-GalCer
both in vitro and in vivo. Moreover, α-LacCer attenuated
α-GalCer, and GSL-1-induced AHR and ConA-triggered
liver injury. As determined by the plate-bound CD1d
binding assay, the pre-loading of α-LacCer prior to α-
GalCer treatment attenuated the stimulatory properties
of α-GalCer, suggesting that α-LacCer competed with
α-GalCer for CD1d binding. In conclusion, this study
characterized the biological function of α-LacCer highlighting
the use of this glycolipid for the clinical treatment of iNKT
cell-associated diseases.
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